key: cord-0315551-nvrv1icy authors: Ruel, Hélène L.M.; Watanabe, Ryota; Evangelista, Marina C.; Beauchamp, Guy; Auger, Jean-Philippe; Segura, Mariela; Steagall, Paulo V. title: Pain burden, sensory profile and inflammatory cytokines of dogs with naturally-occurring neuropathic pain treated with gabapentin alone or with meloxicam date: 2020-07-22 journal: bioRxiv DOI: 10.1101/2020.07.22.215608 sha: 0baa28a7c2813964990927e2a09f952b32885158 doc_id: 315551 cord_uid: nvrv1icy Canine neuropathic pain (NeuP) has been poorly investigated. This study aimed to evaluate the pain burden, sensory profile and inflammatory cytokines in dogs with naturally-occurring NeuP. Twenty-nine client-owned dogs with NeuP were included in a prospective, partially masked, randomized crossover clinical trial, and treated with gabapentin/placebo/gabapentin-meloxicam or gabapentin-meloxicam/placebo/gabapentin (each treatment block of 7 days; total 21 days). Pain scores, mechanical (MNT) and electrical (ENT) nociceptive thresholds and descending noxious inhibitory controls (DNIC) were assessed at baseline, days 7, 14, and 21. DNIC was evaluated using ΔMNT (after-before conditioning stimulus). Positive or negative ΔMNT corresponded to inhibitory or facilitatory pain profiles, respectively. Data from baseline were compared to those of sixteen healthy controls. ΔMNT, but not MNT and ENT, was significantly larger in controls (2.3 ± 0.9 N) than in NeuP (−0.2 ± 0.7 N). The percentage of dogs with facilitatory sensory profile was similar at baseline and after placebo (61.5-63%), and between controls and after gabapentin (33.3-34.6%). Pain scores were lower than baseline after gabapentin or gabapentin-meloxicam. Cytokine levels were not different between groups or treatments. Dogs with NeuP have deficient inhibitory pain mechanisms. Pain burden was reduced after gabapentin and gabapentin-meloxicam depending on the pain scoring instrument used. . It has been proposed that inflammatory cytokines play a role in the development 53 and maintenance of NeuP and could be an avenue for future therapeutic options [7] . 54 The diagnosis of NeuP in veterinary and cognitively-impaired human patients is a challenge. In 55 companion animal medicine, the disease is diagnosed after appropriate physical, neurological 56 and magnetic resonance imaging (MRI) examination, and clinical signs of pain and allodynia [8] . Owner's written consent was obtained for each patient. Sixteen client-owned healthy control dogs (4.8 ± 2.1 years; 32 ± 16.7 kg; six males and ten 96 females) were recruited simultaneously and their data were used for comparison. They were 97 considered healthy based on history, physical, orthopedic and neurological examinations and did 98 not received any analgesic treatment at least 30 days prior to recruitment. Exclusion criteria were 99 the same as those described below for dogs with NeuP. Data for these individuals were Each dog was randomly allocated to treatment groups 1 or 2 (Table 1) . Randomization 116 was performed using balanced permutations (www.randomization.com). Each treatment was 117 divided into three blocks of 7 days to include gabapentin or gabapentin-meloxicam (either first or 118 third block) or placebo (always during the second block allowing a "wash-out" period between 119 the first and third blocks). The total duration of the study was 21 days. Resting was 120 recommended for all dogs (Fig 1) . obtained 60 seconds apart. If one of the responses received a score of 0 or 1, a third measurement 159 was obtained 60 seconds later. Results with score 0 were not considered for statistical analysis. Outcome data for MNT and ENT were the mean of all measurements from all limbs, obtained 161 with a score ≥1. Electrical nociceptive thresholds -The stimulation was provided using a transcutaneous The ΔMNT (after -before conditioning stimulus) was used as an outcome for the assessment of The DNIC was applied to the "least affected thoracic limb". The latter was based on neurological [10]. They were also both responsible for randomization, recording nociceptive thresholds, regarding the dog's ability to run and to climb stairs were excluded since resting was 202 recommended during the study. Therefore, the sections "pain" (CBPI pain ) and "interference" Serum concentrations of inflammatory cytokines were compared after log 10 transformation. When measures obtained were out of range, they were replaced by the lowest value extrapolated 262 by the software minus 0.01 in order to avoid missing data (and inherent bias). Cytokine analyses 263 were performed using nonparametric test when the distribution of data was asymmetrical (TNF- Twenty-nine dogs completed the study (mean age ± SD: 6.6 ± 3.0 years and mean body weight ± .90 and P = .99) or age (P = .12, P = .76 and P = .25), respectively. Both ENT and MNT were 326 positively associated with body weight (p < .0001) but not ΔMNT (P = .50) ( Table 2) . presentation, 65.4% after gabapentin, 46.2% after gabapentin-meloxicam and 37.0% after 342 placebo (Fig 3) . Pain assessment tools 350 The cumulative score for the CPBI severity and interferences domains were 0 for all 351 control dogs. The CBPI overall impression ranged from very good (n = 2) to excellent (n = 14). The 352 median (range) scores for CMPS-SF for control dogs were 0 (0 -1) and were 5 (0 -9) for NeuP. The treatment order for NeuP did not significantly change the scores of CSOM (P = .07), CBPI 354 pain (P = .064), CBPI interference (P = .15) and CMPS-SF (P = .58). There was no association 355 between sex and age for CSOM (P = .94 and P = .42, respectively), CBPI pain (P = .97 and P = .80, respectively) and CBPI interference (P = .81 and P = .28, respectively). CSOM -Treatment influenced CSOM scores (P < .0001). Higher scores (more difficult to 358 perform a given activity) were attributed by owners at presentation than after each treatment 359 including placebo (Table 3) . 360 Table 3 . Pain scores obtained in dogs with naturally-occurring neuropathic pain before and after CBPI pain -Treatment influenced CBPI pain (P = .002). These scores were higher (more painful) 370 at presentation than after gabapentin or gabapentin-meloxicam (Table 3) . CBPI interference -Treatment influenced CBPI interference (P = .02). These scores were higher at 372 presentation (locomotion more severely affected) than after gabapentin-meloxicam (Table 3) . CBPI overall impression -Treatment influenced CBPI overall impression (P = .0002). These scores were 374 higher (improved overall impression) after gabapentin than at presentation (Table 3) . 19 375 CMPS-SF -Treatment influenced CMPS-SF scores (P = .002). These scores were higher at 376 presentation than after gabapentin and gabapentin-meloxicam and were higher after placebo than 377 gabapentin-meloxicam (Table 3) . Pain scores were higher in male than female dogs (P = .038). Table 4 . No differences were 397 found between groups. Significant effects of sex and body weight were found for some analytes 20 398 (Table 4 and 5). A significant correlation was found between MCP-1 concentrations and the 399 overall impression of the owners on their dogs' quality of life (Tables 6, 7) . A difference in the scores between males and females was recorded with the CMPS-SF. Considering that males were overrepresented in the NeuP group, this could represent a bias in pathologies. Therefore, the lack of significant differences between control and NeuP groups, or 547 between treatments in this study may reflect a type 2 error, more than an actual homogeneity of 548 these populations. A higher concentration of MCP-1 was associated with a worse appreciation of with NeuP before QST at initial presentation. Also, there is no definitive test to diagnose NeuP. Therefore, inclusion criteria were determined to meet the most recent definition of NeuP by the 566 International Association for the Study of Pain: "pain arising as a direct consequence of a lesion or disease affecting the somatosensory system". All dogs included had a long-term history of 568 pain and a confirmed neurological lesion found at MRI. Additionally, most dogs had delayed 569 paw placements or ataxia which indicated an involvement of the somatosensory system. A new definition 32 589 of neuropathic pain Neuropathic pain: principles of diagnosis and treatment Value of 593 quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus Stratifying patients with peripheral neuropathic pain based on sensory profiles: algorithm 597 and sample size recommendations Stratification of neuropathic pain 599 patients: the road to mechanism-based therapy? Conditioned 602 pain modulation predicts duloxetine efficacy in painful diabetic neuropathy Role of the immune system in neuropathic pain Global Pain Council. Guidelines for recognition, assessment and treatment of pain CONSORT 2010 statement: 610 updated guidelines for reporting parallel group randomised trials Feasibility and 613 reliability of electrical, mechanical and thermal nociceptve testing and assessment of 614 diffuse noxious inhibitory control in dogs Pain facilitation and pain inhibition during conditioned pain 616 modulation in fibromyalgia and in healthy controls Multicenter randomized prospective clinical evaluation of 618 meloxicam administered via transmucosal oral spray in client-owned dogs Development and psychometric testing of an 621 instrument designed to measure chronic pain in dogs with osteoarthritis Initial psychometric testing and validation of the 624 French version of the Canine Brief Pain Inventory Development of the 627 short-form Glasgow Composite Measure Pain Scale (CMPS-SF) and derivation of an 628 analgesic intervention score Determination of acute tolerance and hyperalgesia to remifentanil constant 631 rate infusion in dogs undergoing sevoflurane anaesthesia Electrophysiological characterisation of central sensitisation in canine spontaneous 635 osteoarthritis. Pain Pain 637 characterization and response to palliative care in dogs with naturally-occurring 638 appendicular osteosarcoma : An open label clinical trial Diffuse noxious 641 inhibitory controls and nerve injury: restoring an imbalance between descending 642 monoamine inhibitions and facilitations Diffuse noxious inhibitory controls 644 (DNIC) in animals and in man A pilot 646 study investigating whether quantitative sensory testing alters after treatment in patients 647 with fibromyalgia Descending Noradrenergic Inhibition: An Important 649 Mechanism of Gabapentin Analgesia in Neuropathic Pain Stress-induced analgesia Neuronal Plasticity: Increasing the Gain in Pain Paw withdrawal threshold in the von Frey hair test is 35 655 influenced by the surface on which the rat stands Pregabalin for the treatment of syringomyelia-associated neuropathic pain in dogs: A 659 randomised, placebo-controlled, double-masked clinical trial Feasibility and repeatability 661 of cold and mechanical quantitative sensory testing in normal dogs Further evidence for the role of the alpha(2)delta subunit of 664 voltage dependent calcium channels in models of neuropathic pain Systematic 667 review of the management of canine osteoarthritis Prostanoid receptor EP1 and Cox-2 in injured human nerves and a rat model of nerve 670 injury: a time-course study Multimodal approach to therapy-related 672 neuropathic pain in breast cancer Application of ED-674 optimality to screening experiments for analgesic compounds in an experimental model of 675 neuropathic pain Pharmacokinetic/pharmacodynamic relationship of gabapentin in a CFA-induced 678 inflammatory hyperalgesia rat model The use of clinical trial simulation to 680 support dose selection: application to development of a new treatment for chronic 681 neuropathic pain Cytokine concentrations measured by multiplex assay 683 in peripheral blood samples. Vet Path MCP-1 and IL-8 as pain biomarkers in 685 fibromyalgia: a pilot study Neuropathic pain : an updated grading system for research and clinical practice Serum concentrations of gabapentin in dogs S2 Appendix -Dogs with neuropathic pain. A) Scores obtained with Scores obtained with 693 Canine Brief Pain Inventory (CBPI pain and 694 interference), short-form Glasgow Composite Measure Pain Scale (CMPS-SF) shown as 695 mean ± SD B) Values of electrical and mechanical nociceptive thresholds and changes in 696 mechanical nociceptive thresholds after application of a conditioning stimulus in dogs with 697 naturally-occurring neuropathic pain before and after each treatment period. Data are 698 shown as mean ± SD The authors would like to thank Fleur Gaudette from the Pharmacokinetics core facility of the